PMNs from FcγRIIIB WT and null donors are activated more effectively by glycoengineered CD20 antibodies compared with unmodified CD20 antibodies. (A-B) Whole blood from FcγRIIIB donors or the FcγRIIIB-null individual was drawn in desirudin, and 10 µg/mL of the indicated anti-CD20 antibodies or control CTX (CTRL) was added. After 4 hours, PMN activation was measured by staining with anti-CD11b–PE (A) and anti-CD62L–APC (B) antibodies and flow cytometry. The results are the MFI of CD11b and CD62L expression on PMNs relative to irrelevant CTX-treated controls. (C-D) PMNs were purified from peripheral blood of FcγRIIIB WT and null donors and stimulated for 4 hours with CLL B cells opsonized with 10 µg/mL of the indicated CD20 antibodies or CTX (CTRL). PMN activation was measured by staining with anti-CD11b–PE (C) and anti-CD62L–APC (D) antibodies and flow cytometry. The results are the MFI of CD11b and CD62L expression on PMNs. All data are the means and standard deviations of 3 or 4 independent experiments. *P < .05, **P < .01, ***P < .001 vs the respective controls without antibody (CTRL).